Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2020 1
2021 3
2022 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA. Wilson JG, et al. Lancet Respir Med. 2015 Jan;3(1):24-32. doi: 10.1016/S2213-2600(14)70291-7. Epub 2014 Dec 17. Lancet Respir Med. 2015. PMID: 25529339 Free PMC article. Clinical Trial.
BACKGROUND: No effective pharmacotherapy for acute respiratory distress syndrome (ARDS) exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal stem (stromal) cells (MSCs) in the treatm …
BACKGROUND: No effective pharmacotherapy for acute respiratory distress syndrome (ARDS) exists, and mortality re …
Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, Khodadoust MA, Ganjali R, Tafreshian AR, Tavakol-Afshari J. Kaffash Farkhad N, et al. Stem Cell Res Ther. 2022 Jun 28;13(1):283. doi: 10.1186/s13287-022-02920-1. Stem Cell Res Ther. 2022. PMID: 35765103 Free PMC article. Clinical Trial.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is the devastating complication of the new COVID-19 pandemic, directly correlated with releasing large amounts of inflammatory cytokines. Due to their immunoregulatory features, mesenchymal …
BACKGROUND: Acute respiratory distress syndrome (ARDS) is the devastating complication of the new COVID-19 pande …
Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial.
Tonelli R, Pischiutta F, Elice F, Zanier ER, Grisendi G, Astori G, Samarelli AV, Bruzzi G, Manicardi L, Spano C, Nattino G, Signorini F, Bernardi M, Catanzaro D, Merlo A, Lisi I, Pasetto L, Bonetto V, Fiammenghi L, Boschi L, Guidi S, Candini O, Zoerle T, Dander E, D'Amico G, De Pierri F, Maur M, Pettorelli E, Ruggieri V, Cerri S, Mari G, De Berardis G, Mighali P, Baschieri MC, Lazzari L, Bambi F, Ciccocioppo R, Clini E, Dominici M; RESCAT study group. Tonelli R, et al. Cytotherapy. 2025 Sep;27(9):1105-1115. doi: 10.1016/j.jcyt.2025.04.059. Epub 2025 Apr 7. Cytotherapy. 2025. PMID: 40353787 Free article. Clinical Trial.
BACKGROUND AIMS: SARS-CoV-2 infection triggers respiratory inflammation with potentially fatal systemic effects. Mesenchymal stromal/stem cells (MSCs) are promising for treating severe COVID-19 due to their anti-inflammatory and regenerative cap …
BACKGROUND AIMS: SARS-CoV-2 infection triggers respiratory inflammation with potentially fatal systemic effects. Mesenchymal …
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, Hossieni H, Keshel SH, Naderpour Z, Hajizadeh-Saffar E, Shajareh E, Jamaati H, Soufi-Zomorrod M, Khavandgar N, Alemi H, Karimi A, Pak N, Rouzbahani NH, Nouri M, Sorouri M, Kashani L, Madani H, Aghdami N, Vasei M, Baharvand H. Hashemian SR, et al. Stem Cell Res Ther. 2021 Jan 29;12(1):91. doi: 10.1186/s13287-021-02165-4. Stem Cell Res Ther. 2021. PMID: 33514427 Free PMC article. Clinical Trial.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for …
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVI …
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
Grégoire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y. Grégoire C, et al. Front Immunol. 2022 Jul 4;13:932360. doi: 10.3389/fimmu.2022.932360. eCollection 2022. Front Immunol. 2022. PMID: 35860245 Free PMC article. Clinical Trial.
BACKGROUND: Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive mechanical ventilation, and remains associated with high mortality. Given th …
BACKGROUND: Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2 …
Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, Makarem J, Majidzadeh-A K, Hatamkhani A, Moghri M, Danesh A, Haddad-Marandi MR, Sanati H, Abbasvandi F, Arjmand B, Azimi P, Ghavamzadeh A, Sarrami-Forooshani R. Aghayan HR, et al. Stem Cell Res Ther. 2022 Jul 28;13(1):365. doi: 10.1186/s13287-022-02953-6. Stem Cell Res Ther. 2022. PMID: 35902979 Free PMC article. Clinical Trial.
BACKGROUND: High morbidity and mortality rates of the COVID-19 pandemic have made it a global health priority. Acute respiratory distress syndrome (ARDS) is one of the most important causes of death in COVID-19 patients. Mesenchymal stem …
BACKGROUND: High morbidity and mortality rates of the COVID-19 pandemic have made it a global health priority. Acute respiratory d …
Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, McAuley DF, O'Kane C. Gorman E, et al. Trials. 2022 May 13;23(1):401. doi: 10.1186/s13063-022-06220-0. Trials. 2022. PMID: 35562778 Free PMC article.
BACKGROUND: Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative properties. ...Two cohorts of patients, with ARDS due to COVID-19 or ARDS due to other causes, will be recruited and randomised …
BACKGROUND: Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative pr …
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC, Hirani K, Bell CA, Kusack H, Rafkin L, Baidal D, Pastewski A, Gawri K, Leñero C, Mantero AMA, Metalonis SW, Wang X, Roque L, Masters B, Kenyon NS, Ginzburg E, Xu X, Tan J, Caplan AI, Glassberg MK, Alejandro R, Ricordi C. Lanzoni G, et al. Stem Cells Transl Med. 2021 May;10(5):660-673. doi: 10.1002/sctm.20-0472. Epub 2021 Jan 5. Stem Cells Transl Med. 2021. PMID: 33400390 Free PMC article. Clinical Trial.
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 AR …
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal …
Specific Clinical and Immunological Changes Following Mesenchymal Stem Cell Transplantation in COVID-19-induced Acute Respiratory Distress Syndrome Patients: A Phase-I Clinical Trial.
Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, Khodadoust MA, Nikpoor AR, Tavakol Afshari J. Kaffash Farkhad N, et al. Iran J Allergy Asthma Immunol. 2022 Dec 24;21(6):687-703. doi: 10.18502/ijaai.v21i6.11530. Iran J Allergy Asthma Immunol. 2022. PMID: 36640060 Free article.
Acute respiratory distress syndrome (ARDS) is a systemic inflammation resulting from immune system overactivity. ARDS is also a fatal complication of COVID-19. Mesenchymal stem cells (MSCs) have immune modulatory properties. …
Acute respiratory distress syndrome (ARDS) is a systemic inflammation resulting from immune system overactivity. …
Human Umbilical Cord-Derived Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome.
Yip HK, Fang WF, Li YC, Lee FY, Lee CH, Pei SN, Ma MC, Chen KH, Sung PH, Lee MS. Yip HK, et al. Crit Care Med. 2020 May;48(5):e391-e399. doi: 10.1097/CCM.0000000000004285. Crit Care Med. 2020. PMID: 32187077 Clinical Trial.
OBJECTIVES: To investigate the safety, feasibility, and possible adverse events of single-dose human umbilical cord-derived mesenchymal stem cells in patients with moderate-to-severe acute respiratory distress syndrome. ...CONCLUSIONS: Th …
OBJECTIVES: To investigate the safety, feasibility, and possible adverse events of single-dose human umbilical cord-derived mesenchymal …
11 results